Ignite Creation Date:
2024-05-06 @ 7:09 PM
Last Modification Date:
2025-12-17 @ 9:02 AM
Study NCT ID:
NCT05918770
Status:
None
Last Update Posted:
2023-06-26 00:00:00
First Post:
2023-06-05 00:00:00
Brief Title:
Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients
Sponsor:
Hospital Universitario 12 de Octubre
Organization:
Hospital Universitario 12 de Octubre
Study Overview
Official Title:
Telemedicine-guided Patients Reported Outcome Measures (PROMs): Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients
Status:
None
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HALIS
Brief Summary:
validated screening scales used: Gynecologic Cancer Lymphedema Questionnaire (GCLQ) Hospital Anxiety and Depression Scale (HADS) Sexual Function Abbreviated Index (IFSFA-6) Short Nutritional Assessment Questionnaire (SNAQ) Sarcopenia Formulary (SARC-F) along with self-perceived quality of life questionnaires from EORTC: QLQ-C30 EN-24 or OV-28 or CX-24
Detailed Description:
validated screening scales used Gynecologic Cancer Lymphedema Questionnaire GCLQ Hospital Anxiety and Depression Scale HADS Sexual Function Abbreviated Index IFSFA-6 Short Nutritional Assessment Questionnaire SNAQ Sarcopenia Formulary SARC-F along with self-perceived quality of life questionnaires from EORTC QLQ-C30 EN-24 or OV-28 or CX-24
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None